US regulatory status: approved.
pharma · Ph+ ALL · Unresectable or Metastatic Melanoma or Advanced Solid Tumors
Ascentage Pharma
Ascentage Pharma Group
Ascentage Pharma drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
USA HQ
2009 Founded
178 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- USA
- Founded
- 2009
- Employees
- 178
- Programs
- 2
- Drugs
- 3
- Patents
- 0
Ascentage Pharma pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Ascentage Pharma drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Ascentage Pharma in public FDA and regional records. Molecular target: Bcr/Abl fusion protein.
- Target
- Bcr/Abl fusion protein
- Mechanism
- Bcr/Abl fusion protein inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor